Christine Brotschi

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

Journal of medicinal chemistry

ChemMedChem

Science advances

RSC medicinal chemistry

Actelion Pharmaceuticals Ltd

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Actelion Pharmaceuticals Ltd

Switzerland

Senior Scientist :: Drug Discovery Chemistry

Idorsia Pharmaceuticals

Switzerland

Senior Scientist :: Drug Discovery Chemistry

Publications

Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A Ertel, Oliver Nayler, Christine Brotschi, Jodi T Williams, John Gatfield
A uniquely efficacious type of CFTR corrector with complementary mode of action. Science advances 10 (9) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A Ertel, Oliver Nayler, Christine Brotschi, Jodi T Williams, John Gatfield
A uniquely efficacious type of CFTR corrector with complementary mode of action. Science advances 10 (9) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry (2024)
Christine Brotschi, Martin H Bolli, John Gatfield, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T Williams, Christoph Boss
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats. RSC medicinal chemistry 15 (1) (2023)
Christine Brotschi, Martin H Bolli, John Gatfield, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T Williams, Christoph Boss
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats. RSC medicinal chemistry 15 (1) (2023)
Christine Brotschi, Martin H Bolli, John Gatfield, Bibia Heidmann, Francois Jenck, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T Williams, Christoph Boss
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs. ChemMedChem 15 (5) (2020)
Christine Brotschi, Catherine Roch, John Gatfield, Alexander Treiber, Jodi T Williams, Thierry Sifferlen, Bibia Heidmann, Francois Jenck, Martin H Bolli, Christoph Boss
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats. ChemMedChem 14 (13) (2019)

Christine Brotschi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christine Brotschi